Ulcerative Colitis Trials

 A Phase 3b, randomized, multicenter, controlled Study of mirikizumab and placebo or mirikizumab concomitantly administered with tirzepatide in adult participants with moderately to severely active ulcerative colitis and obesity or overweight

A phase IIb, multicenter, double-blind, placebo-controlled induction study with an active treatment extension to assess the efficacy, safety, and pharmacokinetics of RO7837195 in patients with moderately to severely active ulcerative colitis.

A phase 3, randomized, double-blind, placebo-controlled, parallel group, multicenter protocol in adults with an open label study in adolescents to evaluate the efficacy and safety of induction and maintenance therapy with icotrinka in participants with moderately to severely active ulcerative colitis.

A phase 1, randomized, double-blind, placebo-controlled study in healthy participants followed by a randomized, double-blind, placebo-controlled phase 2 study in participants with moderate-to-severe active ulcerative colitis.

 Phase 2b Randomized, double-blind, active-and placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of induction and maintenance combination therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis.